Global design and technology services provider Tata Elxsi has partnered strategically with San Francisco-based software 3.0 AI platform KAVIA AI. The company claims that this is designed to manage millions of lines of code and intricate backend
Fujifilm India, the pioneer in healthcare technology, has introduced Endoveda, a smart endoscopy report management application, at the conference ENDOCON 2025 held in Jaipur.
In one of the most significant advancements in medtech, scientists have presented a smart capsule capable of monitoring and treating inflammation of the gut in real-time, which his manageable via smartphone app...
In a remarkable turn of events in the pharmaceutical trade globally, the API China 2025 has concluded its proceedings with a life-colored presence and thriving industry participation. The main event highlighted booming demand of active pharma...
Novo Nordisk is doubling its India operations as it has launched a major expansion at its Global Business Services (GBS) hub in Bengaluru. In July 2025, the company grew its workforce from 2,500 to over 4,500 employees to reflect its strategy...
City doctors have witnessed a 5-7 times increase in acute liver failure cases linked to Hepatitis A. The significant surge in Hepatitis A-linked acute liver failure cases has been registered post the COVID-19
The Central Drugs Standard Control Organisation (CDSCO) has introduced a QR Code-based appointment booking for stakeholders visiting CDSCO’s headquarters located in the FDA Bhawan at New Delhi
Torrent Pharmaceuticals is preparing to launch semaglutide, both oral and injectable, once the patent for the drug expires in early 2026. This positions Torrent as one of the initial entries in the race for India's pharmaceutical players to get...
The US Food and Drug Administration has given Alembic Pharmaceuticals final approval to market its extended-release carbamazepine tablets in the US. Strengths of 100 mg, 200 mg, and 400 mg are covered by the approval.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended donanemab for the treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology who are heterozygotes
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")